Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
JY Wu, SG Wu, CH Yang, CH Gow, YL Chang… - Clinical Cancer …, 2008 - AACR
Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …
DM Jackman, BY Yeap, LV Sequist, N Lindeman… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
Purpose: In patients with non–small cell lung cancer (NSCLC), mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
First-or second-line therapy with gefitinib produces equal survival in non–small cell lung cancer
JY Wu, CJ Yu, CH Yang, SG Wu, YH Chiu… - American journal of …, 2008 - atsjournals.org
Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K Sugio, H Uramoto, T Onitsuka, M Mizukami, Y Ichiki… - Lung Cancer, 2009 - Elsevier
BACKGROUND: This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …
N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
H Asahina, K Yamazaki, I Kinoshita, N Sukoh… - British journal of …, 2006 - nature.com
Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …
[HTML][HTML] Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer
A Hata, H Yoshioka, S Fujita, K Kunimasa, R Kaji… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Mutation of the epidermal growth factor receptor (EGFR) gene can predict the
efficacy of EGFR-tyrosine kinase inhibitors. Different mutations have been shown to co-occur …
efficacy of EGFR-tyrosine kinase inhibitors. Different mutations have been shown to co-occur …
[HTML][HTML] Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
Introduction: We evaluated the efficacy of gefitinib monotherapy prospectively in patients
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …
[HTML][HTML] Effectiveness of gefitinib against non–small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q
S Watanabe, Y Minegishi, H Yoshizawa… - Journal of thoracic …, 2014 - Elsevier
Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …